Adult Dosing

Xerostomia, Sjogren Syndrome related

• 30 mg PO tid
• Max: 90 mg/day

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Dry mouth, Sjogren Syndrome related

• Hypersensitivity to any of the ingredients of the product
• Uncontrolled asthma
• Angle-closure glaucoma
• Acute iritis

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Use with caution under close medical supervision in patients with hx of cardiovascular disorder evidenced by angina pectoris or MI as therapy may alter cardiac conduction or heart rate
• Use with caution and under close medical supervision in patients with controlled asthma, chronic bronchitis, or chronic COPD as cevimeline may increase airway resistance, bronchial muscle tone and bronchial secretions
• It may cause visual blurring and impairment of depth perception, which may result in decreased visual acquity especially at night and in patients with central lens changes; use with caution while driving at night or performing hazardous activities in reduced lighting
• Monitor for cevimeline toxicity characterized by an exaggeration of its parasympathomimetic effect
• Drugs that inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Use with caution in individuals known or suspected to be deficient of CYP2D6 activity

Cautions: Use cautiously in

• Cardiovascular disease including angina pectoris or prior MI
• Impaired pulmonary function including asthma, chronic bronchitis or COPD
• Hx of biliary disease
• Cholelithiasis
• Nephrolithiasis
• Elderly population

Pregnancy Category:C

Breastfeeding: Safety unknown; manufacturer recommends discontinuation of breastfeeding, or postponing of treatment (taking into account the importance of the drug to the mother).

• CV: Arrhythmias, AV block, severe hypotension, bradycardia, hypertension, palpitations
• CNS: Headache, dizziness, fatigue, tremor
• DERM: Excessive sweating, edema
• GI: Nausea, vomiting, diarrhea, dyspepsia, excessive salivation, cholelithiasis, cholecystitis, salivary gland enlargement, GI irritation, biliary spasm
• GU: UTI
• MUSC: Back pain, arthralgia
• RESP: URTI, rhinitis, cough, bronchospasm, dehydration
• EENT: Sinusitis, conjunctivitis, blurred vision, decreased visual acuity, impaired depth perception, visual disturbances, miosis

• Cholinergic agonist; increases secretion of salivary and sweat glands, and increase tone of the smooth muscle in the GI and urinary tracts by stimulating muscarinic cholinergic receptors
• Rapidly absorbed following oral administration
• Metabolized by liver; CYP450: 2D6, 3A3/4 substrate
• Renally excreted: 97% (16% unchanged); feces: 0.5%
• Half-life: 5 +/- 1 hrs

US Trade Name(s)

• Evoxac

US Availability

cevimeline (generic)

• CAPS: 30 mg

Evoxac

• CAPS: 30 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

ENT

Cholinergic Agonists (Dry Mouth Treatment)

Pricing data from www.DrugStore.com in U.S.A.

• Evoxac 30 MG CAPS [Bottle] (DAIICHI PHARMACEUTICAL CORP)
  30 mg = $95.99
  90 mg = $268.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Evoxac 30 MG Oral Capsule

Pill Image:

[
See full size image]

Ingredient(s): Cevimeline

Imprint: EVOXAC;30;mg

Color(s): White

Shape: Capsule

Size (mm): 15.00

Score: 1

Inactive Ingredient(s): lactose monohydrate / hydroxypropyl cellulose / magnesium stearate

Drug Label Author:
Daiichi Sankyo Pharma Development

DEA Schedule:
Non-Scheduled